DRUG‐ASSOCIATED ALOPECIA
1995; Wiley; Volume: 34; Issue: 3 Linguagem: Inglês
10.1111/j.1365-4362.1995.tb01556.x
ISSN1365-4632
Autores Tópico(s)Drug-Induced Adverse Reactions
ResumoInternational Journal of DermatologyVolume 34, Issue 3 p. 149-158 DRUG-ASSOCIATED ALOPECIA PETER J. PILLANS M.D., Corresponding Author PETER J. PILLANS M.D. From the Centre for Adverse Reactions Monitoring and National Toxicology Group, University of Otago Medical School, Dunedin, New Zealand, and the Drug Information Service, Dunedin Hospital, Dunedin, New Zealand.Address for correspondence: Peter J. Pillans, M.D., National Toxicology Group, University of Otago Medical School, P.O. Box 913, Dunedin, New Zealand.Search for more papers by this authorDAVID J. WOODS M.R. Pharm.S., DAVID J. WOODS M.R. Pharm.S. From the Centre for Adverse Reactions Monitoring and National Toxicology Group, University of Otago Medical School, Dunedin, New Zealand, and the Drug Information Service, Dunedin Hospital, Dunedin, New Zealand.Search for more papers by this author PETER J. PILLANS M.D., Corresponding Author PETER J. PILLANS M.D. From the Centre for Adverse Reactions Monitoring and National Toxicology Group, University of Otago Medical School, Dunedin, New Zealand, and the Drug Information Service, Dunedin Hospital, Dunedin, New Zealand.Address for correspondence: Peter J. Pillans, M.D., National Toxicology Group, University of Otago Medical School, P.O. Box 913, Dunedin, New Zealand.Search for more papers by this authorDAVID J. WOODS M.R. Pharm.S., DAVID J. WOODS M.R. Pharm.S. From the Centre for Adverse Reactions Monitoring and National Toxicology Group, University of Otago Medical School, Dunedin, New Zealand, and the Drug Information Service, Dunedin Hospital, Dunedin, New Zealand.Search for more papers by this author First published: March 1995 https://doi.org/10.1111/j.1365-4362.1995.tb01556.xCitations: 43 The conclusions reached in this review reflect the judgment of the authors and do not represent the opinion of the WHO or their individual organizations. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Levantine A., Almeyda J. Drug-induced alopecia. Br J Dermatol 1973; 89: 549–553. 2 Weigand DA. Recent developments in alopecias. Int J Dermatol 1978; 17: 280–286. 3 Blankenship ML. Drugs and alopecia. Australas J Der matol 1983; 24: 100–104. 4 Brodin MB. Drug-related alopecia. Dermatol Clin 1987; 5: 571–579. 5 Tosti A, Misciali C, Piraccini BM, et al. Drug-induced hair loss and hair growth. Incidence, management and avoidance. Drug Safety 1994; 10: 310–317. 6 A Rook, R Dawber, eds. Diseases of the hair and scalp. 2nd Ed. Oxford : Blackwell Scientific, 1982: 1. 7 Jakubovic HR, Ackerman AB. Structure and function of skin: development, morphology, and physiology. In: SL Moschella, HJ Hurley, eds. Dermatology. 2nd Ed. Philadelphia : WB Saunders, 1985: 1. 8 Randall VA, Ebling FJG. Seasonal changes in human hair growth. Br J Dermatol 1991; 124: 146–151. 9 Delaunay M. Effets cutanés indésirables de la chimiothérapie antitumorale. Ann Dermatol Venereol 1989; 116: 347–361. 10 Dunagin WG. Clinical toxicity of chemotherapeutic agents: dermatologic toxicity. Semin Oncol 1982; 9: 14–22. 11 Crounse RG, Van Scott EJ. Changes in scalp hair roots as a measure of toxicity from cancer chemotherapeutic drugs. J Invest Dermatol 1960; 35: 83–90. 12 Kligman AM. Pathologic dynamics of human hair loss. I. Telogen effluvium. Arch Dermatol1961; 83: 175–198. 13 Champion RH, Burton JL, Ebling FJG. Textbook of dermatology. 5th Ed. Oxford : Blackwell Scientific, 1992: 2582. 14 Bork K. Undesirable drug reactions affecting the hair and nails. In: K Bork, ed. Cutaneous side effects of drugs. Philadelphia : WB Saunders, 1988: 249. 15 Wintroub BU, Stern R. Cutaneous drug reactions: pathogenesis and clinical classification. J Am Acad Der matol 1985; 13: 167–179. 16 Samanta A, Jones GR, Burden AC. Adverse reactions during treatment with amiodarone hydrochloride. BMJ 1983; 287: 503. 17 Samuel LM, Davie M, Starkey IR. Amiodarone and hair loss. Postgrad Med J 1992; 68: 771. 18 Smit AJ, Hoorntje SJ, Donker AJM. Zinc deficiency during captopril treatment. Nephron 1983; 34: 196–197. 19 Motel PJ. Captopril and alopecia: a case report and review of known cutaneous reactions in captopril use. J Am Acad Dermatol 1990; 20: 124–125. 20 Leaker B, Whitworth AJ. Alopecia associated with captopril treatment. Aust NZ J Med 1984; 14: 866. 21 Ahmad S. Enalapril and reversible alopecia. Arch Intern Med 1991; 151: 404. 22 Baker H, Levene GM. Cutaneous reactions to anticoagulants. Brit J Dermatol 1969; 81: 236–238. 23 Fischer R, Burcher R, Reith T. Der Haarausfall nach antikoagulierender Therapie. Schweiz Med Wochenscbr 1983; 83: 509–513. 24 Umlas J, Harken DE. Warfarin-induced alopecia. Cutis 1988; 42: 63–64. 25 Caron J, Libersa C. Drugs affecting blood clotting, fibrinolysis and haemostasis. In: MNG Dukes, ed. Meyler's side effects of drugs. 12th Ed. Amsterdam : Elsevier, 1992: 898. 26 De Spain JD. Dermatologic toxicity of chemotherapy. Semin Oncol 1992; 19: 501–507. 27 Joss RA, Kiser J, Weston S, et al. Fighting alopecia in cancer chemotherapy. Recent Results Cancer Res 1988; 108: 117–126. 28 Jessen RT, Straight M, Smith EB. Cutaneous and other complications of cyclophosphamide: A brief review. Rock Mount Med J 1978; 75: 204–206. 29 Kennedy BJ, Theologides A. The role of 5-fluorouracil in malignant disease. Ann Intern Med 1961; 55: 719–730. 30 Ma HK, Gip SK, Chun D. Actinomycin D for methotrexate-resistant trophoblastic tumours. J Obstet Gynaecol 1971; 78: 166–171. 31 Boiron M, Jacquillat C, Weil M, et al. Daunorubicin in the treatment of acute myelocytic leukaemia. Lancet 1969; i: 300–333. 32 Bonadonna G, Monfardini S, DeLena M, et al. Clinical evaluation of adriamycin, a new antitumour antibiotic. BMJ 1969; 3: 503–506. 33 Yagoda A, Mukherji B, Young C, et al. Bleomycin an antitumor antibiotic. Clinical experience in 274 patients. Ann Intern Med1972; 77: 861–870. 34 Rhomberg WU. Vindesine for recurrent and metastatic cancer of the uterine cervix. A phase II study. Cancer Treat Rep1986; 70: 1455–1457. 35 De Spain JD. Dermatologic toxicity. In: MC Perry, ed. The chemotherapy source book. Baltimore : Williams & Wilkins, 1992: 531–533. 36 Hood AF. Cutaneous side effects of cancer chemotherapy. Med Clin North Am 1986; 70: 187–190. 37 Weinstein CD. Methotrexate. Ann Intern Med 1977; 86: 199–204. 38 Hodes ME, Rohn RJ, Bond WH, et al. Vincaleukoblastine. IV: A summary of two and one half year's experience in the use of vinblastine. Cancer Chemother Rep1962; 16: 401–406. 39 Holland JF, Scharlov C, Gailani S, et al. Vincristine treatment of advanced cancer: A co-operative study of 392 cases. Cancer Res 1973; 33: 1258–1264. 40 O'Dwyer PJ, Leyland-Jones B, Alonso MT, et al. Etoposide (VP-16-2134): current status of an active anticancer drug. N Engl J Med 1985; 312: 692–700. 41 Phillips GL, Wolff SN, Fay JW, et al. Intensive 1,3-bis (2-chloroethyl)-1 -nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. J Clin Oncol 1986; 4: 639–645. 42 Kennedy BJ, Smith LR, Goltz RW. Skin changes secondary to hydroxyurea therapy. Arch Dcrmatol 1975; 111: 183–187. 43 Papadopoulos S, Harden, R Mc, G. Hair loss in patients treated with carbimazole. BMJ 1966; 2: 1502–1503. 44 Martin CM, Southwick EG, Maibach HI. Propranolol-induced alopecia. Am Heart J 1973; 86: 236–237. 45 Scribner MD. Propranolol therapy. Arch Dermatol 1977; 113: 1303. 46 Hilder RJ. Propranolol and alopecia. Cutis 1979; 24: 63–64. 47 England JRF, England JDF. Alopecia and propranolol therapy. Aust Fam Physician 1982; 11: 225–226. 48 Graeber GW, Lapkin RA. Metoprolol and alopecia. Cutis 1981; 28: 633–634. 49 de Soyza N, Kane JJ, Murphy ML, et al. The long term suppression of ventricular arrhythmia by oral acebutalol in patients with coronary artery disease. Am Heart J 1980; 100: 631–638. 50 Fravmfelder FT, Menacker SJ. Alopecia possibly secondary to topical ophthalmic beta-blockers. JAMA 1990; 263: 1493–1494. 51 Fabre N, Montastruc JL, Rascol O. Alopecia: an adverse effect of bromocriptine. Clin Neuropharmacol 1993; 16: 266–268. 52 Blum I, Leiba S. Increased hair loss as a side effect of bromocriptine treatment. N Engl J Med 1980; 303: 1418. 53 Khalsa JH, Graham GF, Jones JK. Cimetidine-associated alopecia. Int J Dermatol 1983; 22: 202–204. 54 Ahmad S. Gimetidine and alopecia. Ann Intern Med 1979; 91: 930. 55 Vircburger MI, Prelevic GM, Brkic S, et al. Transitory alopecia and hypergonadotrophic hypogonadism during cimetidine treatment. Lancet 1981; i: 1160–1161. 56 Aram H. Treatment of female androgenetic alopecia with cimetidine. Int J Dermatol 1987; 26: 128–130. 57 Malkinson ED, Lynfield YL. Colchicine alopecia. J Invest Dermatol 1959; 33: 371–378. 58 Mikkleson WM. Alopecia totalis after colchicine treatment for acute gout. N Engl J Med 1956; 255: 766–770. 59 Mareth TR. Hair loss associated with fluoxetine use in two family members. J Glin Psychiatry 1994; 55: 163. 60 Jenike MA. Severe hair loss associated with fluoxetine use. Am J Psychiatry 1991; 148: 392. 61 Ananth J, Elmishaugh A. Hair loss associated with fluoxetine treatment. Can J Psychiatry 1991; 36: 621. 62 Ogilvie AD. Hair loss during fluoxetine treatment. Lancet 1993; 342: 1423. 63 Gupta S, Major LF. Hair loss associated with fluoxetine. Br J Psychiatry 1991; 159: 737–738. 64 Rosenbaum EE, Rosenbaum RB. Chrysotherapy. Arch Intern Med 1979; 139: 1316. 65 van Riel PLGM. Metals. In: MNG Dukes, ed. Meyler's side effects of drugs. 12th Ed. Amsterdam : Elsevier, 1992: 523, 526. 66 Ingimarsson S, Cantell K, Strander H. Side effects of long term treatment with human leukocyte interferon. J Infect Dis 1979; 140: 560–563. 67 Priestman TJ. Interferon: an anti-cancer agent Cancer Treat Rev 1979; 6: 223–227. 68 Tosti A, Misciali G, Bardazzi F, et al. Telogen effluvium due to recombinant interferon alpha–2b. Dermatology 1992; 184: 124–125. 69 Orwin A. Hair loss following lithium therapy. Br J Dermatol 1983; 108: 503–504. 70 McCreadie RG, Morrison DP. The impact of lithium in South West Scotland: demographic and clinical findings. Br J Psychiatry 1985; 146: 70–74. 71 Mortimer PS, Dawber RPR. Hair loss and lithium. Int J Dermatol 1984; 23: 603–604. 72 Yassa R. Hair loss during lithium therapy. Am J Psychiatry 1986; 143: 943. 73 Muniz GE, Salem RB, Director KL. Hair loss in a patient receiving lithium. Psychosomatics 1982; 23: 312. 74 Jefferson JW, Greist JH, Diamond RL, et al. Lithium and hair loss. Int Drug Ther Newsletter 1979; 14: 23. 75 Yassa R, Ananth J. Hair loss in the course of lithium treatment: a report of 2 cases. Can J Psychiatry 1983; 28: 132–133. 76 Ingles RM, Kahn T. Unusual hair changes with minoxidil therapy. Int J Dermatol 1983; 22: 120–122. 77 Kidwai BJ, George M. Hair loss after minoxidil withdrawal. Lancet 1992; 340: 609–610. 78 Cormia FE. Alopecia from oral contraceptives. JAMA 1967; 201: 635–637. 79 Anon. Hair loss and contraceptives. BMJ 1973; 2: 499–500. 80 Hanson SN, Kuylen K, Bjorkman AB. Hair loss and scaling with proguanil. Lancet 1989; i: 225. 81 Inkeles SB, Gonnor WE, Illingworth DR. Hepatic and dermatologic manifestations of chronic hypervitaminosis A in adults. Am J Med 1986; 80: 491–496. 82 Muenter MD, Perry HO, Ludwig J. Chronic vitamin A intoxication in adults: hepatic, neurologic and dermatologic complications. Am J Med 1971; 50: 129–136. 83 Berth-Jones J, Shuttleworth D, Hutchinson PE. A study of etretinate alopecia. Br J Dermatol 1990; 122: 751–755. 84 Grekin RG, Ellis GN, Voorhees JJ. Retinoids in the treatment of psoriasis. Monotherapy and combination. Dermatol Clin1984; 2: 439–454. 85 Pillans PI, Wood DJ. Alopecia associated with sulfasalazine. Drug Investigation 1994; 7: 113–116. 86 Attar A, Anuras S. Sulfasalazine and hair loss. Gastroenterology 1981; 80: 102.[Abstr]. 87 Codeluppi PL, Chahin NJ, Merighi A, et al. A complication of SASP (sulfasalazine) therapy: hair loss. Dig Dis Sci 1987; 32: 221–222. 88 Fich A, Eliakim R. Does sulfasalazine induce alopecia J Clin Gastroenterol 1988; 10: 466. 89 Taffet SL, Das KM. Desensitization of patients with inflammatory bowel disease to sulfasaiazine. Am J Med 1982; 73: 520–524. 90 Kutty PK. Hair loss and 5-aminosalicylic acid enemas. Ann Intern Med 1982; 97: 785–786. 91 Schaumburg HW, Berger A. Alopecia and sensory polyneuropathy from thallium in Chinese herbal medication. JAMA 1992; 268: 3430–3431. 92 Reed D, Crowley J, Faros N. Thallotoxicosis. JAMA 1963; 183: 516–522. 93 Heyl T, Barlow RJ. Thallium poisoning: a dermatological perspective. Br J Dermatol 1989; 121: 787–792. 94 Baral J, Deakins S. Imipramine-induced alopecia areata-like lesions. Int J Dermatol 1987; 26: 198. 95 Warnock JK, Sieg K, Willsie D, et al. Drug-related alopecia in patients treated with tricyclic antidepressants. J Nerv Ment Dis 1991; 179: 441–442. 96 Lewis JR. Valproic acid (Depakene). A new anticonvulsant agent. JAMA1978; 240: 2190–2192. 97 Koch-Weser J, Browne TR. Valproic acid. N Engl J Med 1980; 302: 661–666. 98 Jeavons PM, Clark JE. Sodium valproate in treatment in epilepsy. BMJ 1974; 2: 584–586. 99 Hassan MN, Laljee HCK, Parsonage MJ. Sodium valproate in the treatment of resistant epilepsy. Acta Neurol Scand 1976; 54: 209–218. 100 Barter DAC. Hair loss in a child associated with naproxen. BMJ 1988; 298: 325. 101 Barth JH, Dawber RPR. Drug-induced hair loss. BMJ 1989; 298: 675. 102 Meyer HC. Alopecia associated with ibuprofen. JAMA 1979; 242: 142. 103 Rawnsley HM, Shelley WB. Salicylate ingestion and idiopathic hair loss. Lancet 1968; i: 567–569. 104 Garcier-Muret MP, Sitjas D, Tuneu L, de Moragas JM. Telogen effluvium associated with albendazole therapy. Int J Dermatol 1990; 29: 669–670. 105 Yoshioka H, Matsuda L. Loss of hair related to gentamicin treatment. JAMA 1970; 211: 123. 106 Auerbach R, Orentreich N. Alopecia and ichthyosis secondary to allopurinol. Arch Dermatol 1968; 98: 104. 107 Marshall A, Williams MJ. Alopecia and levodopa. BMJ 1971; 2: 47. Citing Literature Volume34, Issue3March 1995Pages 149-158 ReferencesRelatedInformation
Referência(s)